Clariant Reports Improved Q2 Results; Sees Growth Extending To Q3

Specialty chemical company Clariant AG (CRN.L) on Thursday announced 12% increase in sales from continuing operations in the second quarter to CHF 1.032 billion from CHF926 million last year, driven by sales growth in all regions, reflecting a demand recovery.

EBITDA for the quarter rose to CHF173 million from CHF135 million a year ago.

EBITDA, excluding items, was CHF178 million compared with CHF146 million last year.

Net result from continuing operations for the first half rose to CHF107 million from CHF75 million during the prior-year period.

For the third quarter, Clariant said it expects continued strong growth for the Group in local currency versus the prior year

Looking forward to the full year 2021, Clariant expects to achieve local currency sales growth in continuing operations in a range of 7 % - 9 %.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT